ORPHA:424002
Squamous cell carcinoma of the rectum
Also known as: Rectal squamous cell carcinoma
Publications
670
83.2th percentile
Trials
4
Interventional, condition-specific
Researchers
1,100
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare epithelial tumor of the rectum, arising from squamous cells in the rectal epithelium, without the presence of squamous-lined fistulous tracts in the rectum or a proximal extension of SCC of anal or gynecological origin. The reported symptoms are often nonspecific, such as anorexia, weight loss, lower abdominal pain, rectal bleeding and changes of bowel habits.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018515
- UMLS:C1335690
- NCIT:C5554
Additional Mondo synonyms (8)
rectal squamous carcinoma · rectal squamous cell cancer · rectal squamous cell carcinoma · rectum squamous cell carcinoma · squamous carcinoma of rectum · squamous carcinoma of the rectum · squamous cell carcinoma of rectum · squamous cell carcinoma of the rectum
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
670 matched papers (498 in last 10 years) Source
- Phenotype characterisedPresent
12 HPO annotations (e.g. Anal canal squamous cell carcinoma; Neoplasm of the rectum; Neoplasm of the liver) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
4 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
12
Associated phenotypes · MONDO:0018515
- Anal canal squamous cell carcinoma
- Neoplasm of the rectum
- Neoplasm of the liver
- Neoplasm of the skeletal system
- Neoplasm of the lung
Showing 5 of 12 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
10
Drugs / clinical candidates · MONDO_0018515
- BINTRAFUSP ALFA·phase 2
- CISPLATIN·phase 2
- FLUOROURACIL·phase 2
- SACITUZUMAB TIRUMOTECAN·phase 2
- SINTILIMAB·phase 2
- NIVOLUMAB·phase 1
- PEMBROLIZUMAB·phase 1
- VOROLANIB·phase 1
- IMMUNOCYTOKINE NHS-IL12·phase 1 2
- PEXIPEPIMUT-S·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
670
670 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
670 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
498 in the last 10 years · high confidence · 83.2th percentile (publications denominator)
Phrase hits: 670 · MeSH hits: 0
Who's working on it?
1,100
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhang Y6 papers · 2025
Department of Cancer Testing Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
Papers in Europe PMC - 02Liu J5 papers · 2026
Department of Oral Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Papers in Europe PMC - 03Wang L5 papers · 2026
Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, 266000, China. wl1031@126.com.
Papers in Europe PMC - 04Wang X5 papers · 2025
School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Papers in Europe PMC - 05Li X4 papers · 2026
School of Basic Medical Sciences, State Key Laboratory of Metabolic Dysregulation & the Prevention and Treatment of Esophageal Cancer, Zhengzhou University, Zhengzhou, Henan, 450001, China.
Papers in Europe PMC - 06Liu Z4 papers · 2025
Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan, China.
Papers in Europe PMC - 07Wang Q4 papers · 2026
Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Papers in Europe PMC - 08Wang R4 papers · 2025
Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, 266000, China.
Papers in Europe PMC - 09Xu X4 papers · 2026
Department of Gastroenterological Surgery Peking University People's Hospital Beijing China.
Papers in Europe PMC - 10Yang Y4 papers · 2026
Department of Oral and Maxillofacial Surgery, Hebei Eye Hospital, Xingtai, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
4
interventional trials for this specific condition
4 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 2,552 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
4 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 88.1th percentile).
high confidence · 88.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
4 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06364384·RECRUITING·Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma
Not reviewed·Conditions: Rectal Squamous Cell Carcinoma·Matched via name phrase
- NCT05686226·RECRUITING·E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Not reviewed·Conditions: Cervical Cancer · Throat Cancer · Oropharynx Cancer · Anal Cancer·Matched via name phrase
Broader category: squamous cell carcinoma
2,552
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT06599775·NOT YET RECRUITING·Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Not reviewed·Conditions: Resectable Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT07487896·RECRUITING·A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not reviewed·Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07629817·NOT YET RECRUITING·Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07392580·RECRUITING·Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 15 · after dedupe 15 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 15 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (15)
- isrctn·ISRCTN78380445·Recruiting·A clinical trial testing a new treatment called mRNA-4194 for people with Lynch syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16847938·No longer recruiting·A study to evaluate the safety, tolerability, processing by the body and mechanism of action of RO7486967 in participants with ulcerative colitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90009147·No longer recruiting·Trifluridine/tipiracil (FTD/TPI) quality of life study in mCRC patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74358648·No longer recruiting·Add-Aspirin: the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70833965·No longer recruiting·A phase II double-blind, randomised controlled trial of VEGF inhibitor axitinib monotherapy with early dynamic contrast-enhanced ultrasound monitoring in chemo-refractory third-line metastatic colorectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59158409·No longer recruiting·Radiotherapy, Irinotecan, Capecitabine then Excision for locally advanced rectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98873899·No longer recruiting·Weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30540872·No longer recruiting·Efficacy and safety of topical SR-T100® gel in the treatment of human cutaneous squamous cell carcinoma in situ (actinic keratosis and Bowen's disease)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58864837·No longer recruiting·CINATRA: Chromosomal Instability and Anti-Tubulin Response Assessment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99195212·No longer recruiting·An open, randomised, multicentre trial of Tomudex (ZD1694) versus 5-Fluorouracil (5-FU) and Leucovorin (LV) in patients with advanced colorectal carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15067672·No longer recruiting·A randomised multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and removing as many visible tumors as possible by surgery or other means versus chemotherapy alone
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17627211·No longer recruiting·The PACE Study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98496463·No longer recruiting·Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve quality of life in cancer survivors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45133151·No longer recruiting·Multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the rectum — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the rectum" OR "Squamous cell carcinoma of rectum" OR "Rectal squamous cell carcinoma" OR "rectal squamous carcinoma" OR "rectal squamous cell cancer" OR "rectum squamous cell carcinoma" OR "squamous carcinoma of rectum" OR "squamous carcinoma of the rectum"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the rectum" OR "Squamous cell carcinoma of rectum" OR "Rectal squamous cell carcinoma" OR "rectal squamous carcinoma" OR "rectal squamous cell cancer" OR "rectum squamous cell carcinoma" OR "squamous carcinoma of rectum" OR "squamous carcinoma of the rectum"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 4 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:54:48.517Z
